Kiniksa Pharmaceuticals International, plc (KNSA): Total Liabilities
$196.03M
As of 2025-12-31
$219.59M
As of 2026-03-31
+45.6%
3-year compound annual growth
+39.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $196.03M | +37.9% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $142.12M | +62.5% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $87.48M | +37.7% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $63.52M | +33.0% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $47.76M | +27.3% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $37.53M | +28.9% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $29.11M | -31.8% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $42.70M | +145.0% | 2020-03-05, Balance as of period end |
| 2017-12-31 | $17.43M | n/a | 2019-03-12, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $196.03M | +37.9% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $1.60B | +29.3% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $390.93M | +17.6% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $601.51M | +17.6% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $840.49M | -0.6% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $571.81M | -26.2% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $796.00M | -12.2% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $415.23M | +16.9% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $663.99M | -20.5% |
Compare KNSA, RARE, SUPN, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗